12/20/2024

Provepharm wishes you a very happy new year! The entire Provepharm team wishes you health, happiness, and success in both your professional and personal endeavors. We would also like to thank all our clients, partners, and employees for their continued trust. Discover our New Year's greetings! 

09/10/2024

On September 19 and 20, the AFC congress will be held, this year dedicated to surgical emergencies. Provepharm is partnering this event for the 1st time, with a booth (n°11) and the organization of a symposium presented by Pr Rouprêt and Pr Lefèvre. The symposium will focus on the management of ureteral lesions during complex visceral surgery.

Over the 2 days, Provepharm's sales, marketing and medical teams will be delighted to discuss the importance of dyes in the surgical management of patients.

09/09/2024

Blumyne™ provides healthcare professionals and hospitals with new, cost-efficient alternative indigo carmine dye for pelvic and abdominal surgery

Marseille, France, September 9, 2024 - Provepharm, a leading international pharmaceutical company specialising in medical dyes and antidotes, today announces the commercial launch of the licensed medicine Blumyne™ 40 mg/5 mL, solution for injection on to the UK market. This indigo carmine (indigotine) dye is a diagnostic agent indicated for the intra-operative detection of suspected ureteral injuries during abdominal and pelvic surgery. 

With only one indigo carmine dye currently licensed as a medicine for surgical use in the UK, the commercial launch of Blumyne™ (40mg/5ml) gives healthcare professionals a new, cost-efficient, therapeutic alternative. By selecting Provepharm, providers gain access to support from an independent company recognised as an expert in the surgical and endoscopic dye market. The opening of the UK affiliate in November 2023 ensures a direct line of customer assistance. 

“I am thrilled to lead the national launch of Blumyne™; much welcomed on the UK market. Provepharm’s years of expertise in the surgical dye market positions the company as a trusted supplier for UK healthcare providers,” said Tim Whelan, UK country manager at Provepharm and head of UK operations. “At Provepharm, we act to improve life and we aim to continue expanding the range of dyes available on the market to provide patients and healthcare professionals with a wider range of therapeutic solutions.” 

Provepharm will continue to develop its range of dyes to cover surgical needs and reinforce knowledge on the benefits of dyes in clinical practice. 

About Provepharm – Act to improve life 
An independent, international specialty pharmaceutical company, Provepharm leverages the potential of well-known molecules to develop innovative solutions that satisfy hospital’s unmet critical needs and help improve patients' lives. Provepharm develops, manufactures and markets a range of hospital products such as antidotes, and endoscopic and surgical dyes. Working closely with healthcare professionals, Provepharm is committed to developing specific services aimed at helping them enhance clinical practices. With a team of over 160 professionals and offices in France, the US and UK, the company markets its products in over 25 countries worldwide and devotes between 20% and 25% of its revenues to R&D. 
The company strives every day to have a positive and significant social, societal and environmental impact in the performance of its activities: that’s its raison d’être. In November 2023, Provepharm joined the exclusive club of pioneering B Corp-certified pharmaceutical companies. www.provepharm.com

03/05/2024

Provepharm will attend the EAHP (European Association of Hospital Pharmacists) congress in Bordeaux 20th to 22th of March 2024.

We will be pleased to welcome European hospital pharmacists on PROVEPHARM both # 67 to present our hospital dyes and our services to improve right usage of dyes. Visitors can also take this opportunity to test their knowledge in our endoscopic and surgical dyes usage thanks to our “Color Quiz”.

03/05/2024

Provepharm will attend the EAHP (European Association of Hospital Pharmacists) congress in Bordeaux 20th to 22th of March 2024.

We will be pleased to welcome European hospital pharmacists on PROVEPHARM both # 67 to present our hospital dyes and our services to improve right usage of dyes. Visitors can also take this opportunity to test their knowledge in our endoscopic and surgical dyes usage thanks to our “Color Quiz”.

12/27/2023

All Provepharm employees wish you happy holidays and All the Best for 2024.

Discover our wishes in video!

11/29/2023

Company joins exclusive club of pioneering B Corp-certified pharmaceutical companies

11/08/2023

Opening will enable pharmaceutical company to better provide UK market with direct distribution and client-facing team. UK third direct-selling country for Provepharm, after France and the United States, expanding commercial presence in medical dye and antidote markets
 

August 2024

Since 2022, Provepharm reached an important milestone in its CSR strategy. In this "2023 CSR Impact, new edition " the essential elements of our approach have been grouped together.

08/08/2023

Provepharm, an international, private and sustainable pharmaceutical company specialized in revitalizing molecules and Pharm-D, a healthcare and pharmaceutical company based in Malaysia with a strong foothold in Singapore, announce today their partnership to launch Proveblue^® 5 mg/ml solution for injection in Malaysia. Proveblue^® is, a methylthioninium chloride product compliant with European Pharmacopeia standards.